Biogen

Biogen Makes Bold Move with $550 Million Investment in New Epilepsy Drug Rights

1 month ago

In a groundbreaking development for the pharmaceutical industry, Biogen has committed up to $550 million for the exclusive rights to a promising new epilepsy treatment. This strategic investment is poised to significantly bolster Biogen's presence in the epilepsy market, an area that has seen burgeoning interest and demand for innovative therapies.

Biogen Surpasses Earnings Expectations Thanks to Alzheimer’s Drug Leqembi

2 months ago

Biogen has delivered an impressive financial performance, exceeding Wall Street's projections for the fourth quarter, primarily driven by the strong sales of its Alzheimer’s treatment, Leqembi. The company reported quarterly sales that not only surpassed analyst forecasts but also indicated a significant resurgence in demand for its pharmaceutical offerings.

FDA Drug Approval Process Under Scrutiny: Insights from Biogen and Sarepta's Rapid Approvals

3 months ago

The recent approvals of drugs from Biogen and Sarepta have sparked significant debate regarding the Federal Drug Administration's (FDA) regulatory processes, raising questions about the thoroughness and consistency of drug reviews. A detailed report indicates that these swift approvals may highlight gaps within the FDA's existing frameworks.

Sage Therapeutics Receives $469 Million Takeover Bid from Biogen: A Game Changer in Neurological Treatments?

3 months ago

In a significant development for the pharmaceutical sector, Sage Therapeutics, a leader in the field of brain health, has attracted attention with a substantial takeover offer from Biogen totaling $469 million. This unexpected bid marks a pivotal moment for Sage, known for its innovative approaches to treating neurological disorders. The proposal comes as both companies strive to enhance their portfolios and capabilities in the competitive biopharmaceutical market.

Biogen Boosts Forecast as Leqembi Shows Promising Growth in Alzheimer's Treatment

5 months ago

In a significant development for the biopharmaceutical sector, Biogen Inc. has raised its financial projections for the upcoming periods due to the encouraging performance of its Alzheimer's treatment, Leqembi. The announcement came on the heels of a third-quarter earnings report, which revealed that the drug has started to gain traction in the market, signaling potential advancement in Biogen’s business trajectory amidst ongoing challenges in the healthcare industry.